The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The U.S. recorded 2,280 measles cases in 2025, the highest since 1991, with 982 cases already confirmed in early 2026. North London faces an outbreak with 34 children infected in Enfield, while Philadelphia issued an exposure alert for the international airport.
A measles exposure occurred on February 18 at Nemours Children's Hospital emergency department in Delaware. State health officials are conducting contact tracing and urging unvaccinated exposed individuals to receive MMR vaccine within 72 hours.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
Measles cases are rising across multiple states, with over 40 cases at a Florida college and 18 cases in North Carolina since December. Federal health officials are urging vaccination as the U.S. recorded 2,280 cases in 2025.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778953 |
90% Effective Infusion Time of Sufentanil to Prevent Induction Cough: A Biased Coin Sequential Study |
NOT_YET_RECRUITING | NA |
| NCT07754279 |
Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT07684586 |
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes |
SUSPENDED | PHASE1 |
| NCT07660380 |
Oliceridine vs Sufentanil for Cough During Anesthesia Induction |
RECRUITING | PHASE4 |
| NCT07427303 |
Focused Echocardiography for Primary Care Physicians |
NOT_YET_RECRUITING | NA |
| NCT07420491 |
The Efficacy and Safety of Reconyl in Acute Cough Treatment |
COMPLETED | PHASE3 |
| NCT07411417 |
Combined Acupressure Effects on Post-Thoracotomy Pain and Lung Volume |
RECRUITING | NA |
| NCT07330856 |
Evaluation of Treatments for Dry or Productive Cough |
RECRUITING | PHASE4 |
| NCT07288528 |
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough |
NOT_YET_RECRUITING | PHASE4 |
| NCT07184372 |
Radiofrequency in Patients Post Covid 19 With Respiratory Sequelae. |
COMPLETED | NA |
